Introduction:
This article discusses the risks associated with the use of viral vectors in cell and gene therapy (CGT) manufacturing. It highlights the safety concerns, manufacturing costs, and potential adverse events that can arise from the use of viral vectors. The article emphasizes the need for alternative non-viral approaches to enhance the safety and efficacy of CGTs.
- The use of viral vectors in CGT manufacturing poses safety risks and complexities, driving up manufacturing costs and increasing the potential for serious adverse events among patients.
- The FDA has issued new warning and guidance documents regarding the oncogenic potential of commonly used viruses in cell therapy manufacturing, further highlighting the risks.
- There is a need to explore alternative non-viral approaches to enhance the safety and efficacy of CGTs, especially as emerging applications extend beyond terminal conditions.
- Electroporation, a non-viral method for delivering genetic material into cells, offers a viable alternative to viral vectors. It allows therapeutic components to enter cells without the need for a delivery vehicle, such as a virus.
- Electroporation allows for the delivery of larger and more complex payloads, offering flexibility and innovation in developing advanced therapies. It also eliminates concerns about replication competent viruses, simplifying manufacturing processes and reducing costs.
Conclusion:
The use of viral vectors in CGT manufacturing poses safety risks and manufacturing complexities. To overcome these challenges and enhance the safety and efficacy of CGTs, developers should explore alternative non-viral approaches like electroporation. Electroporation offers a flexible and innovative method for delivering genetic material into cells, eliminating the need for viral vectors and reducing manufacturing costs. By embracing non-viral alternatives, the field of CGT can overcome viral vector risks and further advance therapeutic development.
